TG Therapeutics (NASDAQ:TGTX) Reaches New 52-Week High at $9.73

TG Therapeutics Inc (NASDAQ:TGTX) reached a new 52-week high on Monday . The company traded as high as $9.73 and last traded at $9.18, with a volume of 3180263 shares. The stock had previously closed at $7.12.

TGTX has been the topic of several research analyst reports. B. Riley started coverage on shares of TG Therapeutics in a report on Wednesday, November 27th. They issued a “buy” rating and a $12.00 price objective on the stock. ValuEngine lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, October 21st. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of TG Therapeutics in a research report on Tuesday, November 12th. BidaskClub raised shares of TG Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, November 7th. Finally, Zacks Investment Research lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $12.95.

The company has a fifty day moving average of $7.22 and a 200-day moving average of $6.94. The company has a quick ratio of 1.00, a current ratio of 1.00 and a debt-to-equity ratio of 2.77.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.33). The firm had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.04 million. TG Therapeutics had a negative net margin of 123,130.93% and a negative return on equity of 2,411.79%. As a group, research analysts forecast that TG Therapeutics Inc will post -1.96 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Millennium Management LLC increased its stake in TG Therapeutics by 6,258.4% during the 3rd quarter. Millennium Management LLC now owns 7,521,910 shares of the biopharmaceutical company’s stock worth $42,235,000 after buying an additional 7,403,611 shares during the period. BlackRock Inc. raised its holdings in TG Therapeutics by 19.5% in the second quarter. BlackRock Inc. now owns 5,304,463 shares of the biopharmaceutical company’s stock valued at $45,883,000 after acquiring an additional 866,572 shares in the last quarter. Vanguard Group Inc. lifted its stake in TG Therapeutics by 19.7% in the second quarter. Vanguard Group Inc. now owns 4,041,122 shares of the biopharmaceutical company’s stock worth $34,955,000 after acquiring an additional 665,380 shares during the last quarter. Sofinnova Investments Inc. lifted its stake in TG Therapeutics by 258.5% in the second quarter. Sofinnova Investments Inc. now owns 1,261,384 shares of the biopharmaceutical company’s stock worth $10,911,000 after acquiring an additional 909,573 shares during the last quarter. Finally, Camber Capital Management LP acquired a new position in TG Therapeutics during the 2nd quarter worth approximately $8,650,000. 48.64% of the stock is owned by institutional investors and hedge funds.

TG Therapeutics Company Profile (NASDAQ:TGTX)

TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.

Featured Article: CD Ladder

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.